Stifel analyst Paul Matteis reiterated a Hold rating on Acadia Pharmaceuticals (NASDAQ: ACAD).The analyst comments "FDA briefing documents on the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE